MHC class II molecules in tumour immunology: Prognostic marker and target for immune modulation

Immunobiology

Volumn 211, Issue 6-8, 2006, Pages 619-625

  Chamuleau, M E D ^a   Ossenkoppele, G J ^a   van de Loosdrecht, A A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CLIP; HLA DM; HLA DO; HLA DR; Invariant Chain; MHC class II; Tumour antigen presentation; Tumour immunology; Vaccination

Indexed keywords

ANTINEOPLASTIC AGENT; DENDRITIC CELL VACCINE; HLA DO ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR VACCINE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; APOPTOSIS; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL PROTOCOL; DISEASE MODEL; DOWN REGULATION; HUMAN; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR CELL;

EID: 33747370433     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2006.05.005     Document Type: Review

References (51)

1. Ansell S.M., Stenson M., Habermann T.M., Jelinek D.F., and Witzig T.E. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J. Clin. Oncol. 19 (2001) 720-726
2. Armstrong T.D., Clements V.K., Martin B.K., Ting J.P., and Ostrand-Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc. Natl. Acad. Sci. USA 94 (1997) 6886-6891
3. Armstrong T.D., Clements V.K., and Ostrand-Rosenberg S. MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. J. Immunol. 160 (1998) 661-666
4. Boshoff C., and Weiss R. AIDS-related malignancies. Nat. Rev. Cancer 2 (2002) 373-382
5. Burnet F.M. Cancer-a biological approach. BMJ 1 (1957) 841-847
6. Busch R., Cloutier I., Sekaly R.P., and Hammerling G.J. Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. EMBO J 15 (1996) 418-428
7. Carlo-Stella C., Di N.M., Turco M.C., Cleris L., Lavazza C., Longoni P., Milanesi M., Magni M., Ammirante M., Leone A., Nagy Z., Gioffre W.R., Formelli F., and Gianni A.M. The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice. Cancer Res. 66 (2006) 1799-1808
8. Chamuleau M.E., Souwer Y., Van Ham S.M., Zevenbergen A., Westers T.M., Berkhof J., Meijer C.J., van de Loosdrecht A.A., and Ossenkoppele G.J. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res. 64 (2004) 5546-5550
9. Chen X., Laur O., Kambayashi T., Li S., Bray R.A., Weber D.A., Karlsson L., and Jensen P.E. Regulated expression of human histocompatibility leukocyte antigen (HLA)-DO during antigen-dependent and antigen-independent phases of B cell development. J. Exp. Med. 195 (2002) 1053-1062
10. Chicz R.M., Urban R.G., Gorga J.C., Vignali D.A., Lane W.S., and Strominger J.L. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178 (1993) 27-47
11. Denzin L.K., and Cresswell P. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell 82 (1995) 155-165
12. Dighe A.S., Richards E., Old L.J., and Schreiber R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1 (1994) 447-456
13. Dissanayake S.K., Thompson J.A., Bosch J.J., Clements V.K., Chen P.W., Ksander B.R., and Ostrand-Rosenberg S. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res. 64 (2004) 1867-1874
14. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., and Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3 (2002) 991-998
15. Finn O.J. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3 (2003) 630-641
16. Fremont D.H., Crawford F., Marrack P., Hendrickson W.A., and Kappler J. Crystal structure of mouse H2-M. Immunity 9 (1998) 385-393
17. Glazier K.S., Hake S.B., Tobin H.M., Chadburn A., Schattner E.J., and Denzin L.K. Germinal center B cells regulate their capability to present antigen by modulation of HLA-DO. J. Exp. Med 195 (2002) 1063-1069
18. Golumbek P.T., Lazenby A.J., Levitsky H.I., Jaffee L.M., Karasuyama H., Baker M., and Pardoll D.M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254 (1991) 713-716
19. Haanen J.B., Baars A., Gomez R., Weder P., Smits M., de Gruijl T.D., von Blomberg B.M., Bloemena E., Scheper R.J., Van Ham S.M., Pinedo H.M., and van den Eertwegh A.J. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol. Immunother. 55 (2006) 451-458
20. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., and Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188 (1998) 2357-2368
21. Kacha A.K., Fallarino F., Markiewicz M.A., and Gajewski T.F. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J. Immunol. 165 (2000) 6024-6028
22. Klein G. Immunological surveillance against neoplasia. Harvey Lect. (1973) 71-102
23. Kropshofer H., Vogt A.B., Moldenhauer G., Hammer J., Blum J.S., and Hammerling G.J. Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J. 15 (1996) 6144-6154
24. Lotteau V., Teyton L., Peleraux A., Nilsson T., Karlsson L., Schmid S.L., Quaranta V., and Peterson P.A. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 348 (1990) 600-605
25. Lyko F., and Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J. Natl. Cancer Inst. 97 (2005) 1498-1506
26. Marchand M., van Baren N., Weynants P., Brichard V., Dreno B., Tessier M.H., Rankin E., Parmiani G., Arienti F., Humblet Y., Bourlond A., Vanwijck R., Lienard D., Beauduin M., Dietrich P.Y., Russo V., Kerger J., Masucci G., Jager E., De Greve J., Atzpodien J., Brasseur F., Coulie P.G., van der Bruggen P., and Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80 (1999) 219-230
27. Martin W.D., Hicks G.G., Mendiratta S.K., Leva H.I., Ruley H.E., and Van Kaer L. H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection. Cell 84 (1996) 543-550
28. Matoba K., Iizuka N., Gondo T., Ishihara T., Yamada-Okabe H., Tamesa T., Takemoto N., Hashimoto K., Sakamoto K., Miyamoto T., Uchimura S., Hamamoto Y., and Oka M. Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. Int. J. Cancer 115 (2005) 231-240
29. Matsushita N., Ghazizadeh M., Konishi H., and Araki T. Association of ovarian tumor epithelium coexpressing HLA-DR and CA-125 antigens with tumor infiltrating cytotoxic T lymphocytes. J. Nippon Med. Sch 70 (2003) 40-44
30. Mattes J., Hulett M., Xie W., Hogan S., Rothenberg M.E., Foster P., and Parish C. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J. Exp. Med. 197 (2003) 387-393
31. Momburg F., Herrmann B., Moldenhauer G., and Moller P. B-cell lymphomas of high-grade malignancy frequently lack HLA-DR, -DP and -DQ antigens and associated invariant chain. Int. J. Cancer 40 (1987) 598-603
32. Morimoto Y., Toyota M., Satoh A., Murai M., Mita H., Suzuki H., Takamura Y., Ikeda H., Ishida T., Sato N., Tokino T., and Imai K. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells. Br. J. Cancer 90 (2004) 844-852
33. Nagy Z.A., Hubner B., Lohning C., Rauchenberger R., Reiffert S., Thomassen-Wolf E., Zahn S., Leyer S., Schier E.M., Zahradnik A., Brunner C., Lobenwein K., Rattel B., Stanglmaier M., Hallek M., Wing M., Anderson S., Dunn M., Kretzschmar T., and Tesar M. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat. Med. 8 (2002) 801-807
34. Ostrand-Rosenberg S., Clements V.K., Terabe M., Park J.M., Berzofsky J.A., and Dissanayake S.K. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. J. Immunol. 169 (2002) 5796-5804
35. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., Meatchi T., Bruneval P., Cugnenc P.H., Trajanoski Z., Fridman W.H., and Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353 (2005) 2654-2666
36. Qi L., Rojas J.M., and Ostrand-Rosenberg S. Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. J. Immunol. 165 (2000) 5451-5461
37. Qiu G., Goodchild J., Humphreys R.E., and Xu M. Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells. Cancer Immunol. Immunother. 48 (1999) 499-506
38. Rimsza L.M., Roberts R.A., Miller T.P., Unger J.M., LeBlanc M., Braziel R.M., Weisenberger D.D., Chan W.C., Muller-Hermelink H.K., Jaffe E.S., Gascoyne R.D., Campo E., Fuchs D.A., Spier C.M., Fisher R.I., Delabie J., Rosenwald A., Staudt L.M., and Grogan T.M. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103 (2004) 4251-4258
39. Roberts, R.A., Wright, G., Rosenwald, A.R., Jaramillo, M.A., Grogan, T.M., Miller, T.P., Frutiger, Y., Chan, W.C., Gascoyne, R.D., Ott, G., Muller-Hermelink, H.K., Staudt, L.M., Rimsza, L.M., 2006. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B cell lymphoma is highly coordinated and related to poor patient survival. Blood. Epub ahead of print (doi:10.1182/blood-2005-11-4742).
40. Romagnoli P., and Germain R.N. The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J. Exp. Med. 180 (1994) 1107-1113
41. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 411 (2001) 380-384
42. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Dudley M.E., Schwarz S.L., Spiess P.J., Wunderlich J.R., Parkhurst M.R., Kawakami Y., Seipp C.A., Einhorn J.H., and White D.E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4 (1998) 321-327
43. Roucard C., Thomas C., Pasquier M.A., Trowsdale J., Sotto J.J., Neefjes J., and van Ham M. In vivo and in vitro modulation of HLA-DM and HLA-DO is induced by B lymphocyte activation. J. Immunol. 167 (2001) 6849-6858
44. Rygaard J., and Povlsen C.O. The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance. Acta Pathol. Microbiol. Scand. [B] Microbiol. Immunol. 82 (1974) 99-106
45. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., Jungbluth A.A., Frosina D., Gnjatic S., Ambrosone C., Kepner J., Odunsi T., Ritter G., Lele S., Chen Y.T., Ohtani H., Old L.J., and Odunsi K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102 (2005) 18538-18543
46. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., and Schreiber R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107-1111
47. Tamori Y., Tan X., Nakagawa K., Takai E., Akagi J., Kageshita T., Egami H., and Ogawa M. Clinical significance of MHC class II-associated invariant chain expression in human gastric carcinoma. Oncol. Rep. 14 (2005) 873-877
48. Thompson J.A., Dissanayake S.K., Ksander B.R., Knutson K.L., Disis M.L., and Ostrand-Rosenberg S. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res. 66 (2006) 1147-1154
49. van den Broek M.E., Kagi D., Ossendorp F., Toes R., Vamvakas S., Lutz W.K., Melief C.J., Zinkernagel R.M., and Hengartner H. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184 (1996) 1781-1790
50. van Ham M., van Lith M., Lillemeier B., Tjin E., Gruneberg U., Rahman D., Pastoors L., van Meijgaarden K., Roucard C., Trowsdale J., Ottenhoff T., Pappin D., and Neefjes J. Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO. J. Exp. Med. 191 (2000) 1127-1136
51. Wang J.C., and Livingstone A.M. Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo. J. Immunol. 171 (2003) 6339-6343